J. Randall “Randy” Owen is Chief Medical Officer of Navitor Pharmaceuticals, the leader in the discovery and development of mTORC1-targeted therapeutics. Randy is responsible for the clinical and regulatory development of Navitor’s pipeline of product candidates across medical and neuropsychiatric illnesses, including NV-5138 which is the first-in-class direct mTORC1 activator in development for treatment resistant depression.

Randy has nearly 20 years of biopharma industry leadership experience in developing drugs across psychiatric, neurologic and rare diseases. Before joining Navitor, Randy was Senior Vice President, Clinical Development and Chief Medical Officer at Acadia Pharmaceuticals Inc. He also served in roles of increasing responsibility at Abbott (now Abbvie), Merck, Bristol-Myers Squibb and Lundbeck. Randy completed his psychiatric residency at Emory University, his Medical Degree at East Tennessee State University, and his Bachelor of Arts degree from Haverford College.